Announcements Trials
Browse Landscape

Status

Completed 75Unknown 8Active not recruiting 7Terminated 6Withdrawn 5Approved for marketing 2

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Head and Neck Neoplasms 1

Interventions

Afatinib 3niraparib 2lenvatinib 2ibrutinib 2abemaciclib 2Trastuzumab 2Sunitinib 2Ramucirumab 2Gefitinib 2Capecitabine 2Abiraterone Acetate 23-Iodobenzylguanidine 2zenocutuzumab 1vorasidenib 1tucatinib 1trilaciclib 1trifluridine tipiracil drug combination 1tovorafenib 1talquetamab 1tafasitamab 1selpercatinib 1sacituzumab govitecan 1ripretinib 1pralsetinib 1ponatinib 1pomalidomide 1pirtobrutinib 1pertuzumab 1olaratumab 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Approved for marketing × INDUSTRY × Gefitinib × Clear all
NCT00684385 2019-03-14

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

AstraZeneca

Approved for marketing
Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT00683306 2018-09-13

Open Label Extension Study With Gefitinib (IRESSAâ„¢) for Completing Trial Patients Who May Benefit From Further Treatment

AstraZeneca

Approved for marketing
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡